Canada Saves CAD2bn Through Pricing Deal
But CGPA Warns Over Increasing Reliance On India And China For Supply
A five-year agreement between the Canadian Generic Pharmaceutical Association and the pan-Canadian Pharmaceutical Alliance has helped to save close to CAD2bn in prescription drug costs in Canada. However, the CGPA has expressed concern over price cuts that are forcing Canada increasingly to rely on supply from lower-cost jurisdictions such as China and India.
You may also be interested in...
The Canadian Generic Pharmaceutical Association and the pan-Canadian Pharmaceutical Alliance have agreed a new three-year national pricing initiative for generic medicines.
After Canada’s five-year pricing agreement for generic drugs expired on 31 March, local off-patent industry association the CGPA and national health alliance the pCPA said the current terms would be extended as they continued to work towards a fresh deal.
Sandoz has announced the appointment of a chairman-designate ahead of its planned separation from parent company Novartis this year. Meanwhile, Canadian industry association the CGPA has also named a new chair and vice-chair, while Formycon has appointed a new CFO.